EcoR1 Capital, LLC recently announced the acquisition of new stake in Atara Biotherapeutics Inc (NASDAQ:ATRA). This fresh investment now brings its stake to 9.88% valued currently at $6.64 million. In addition, Wasatch Advisors, Inc. raised its holdings by 0.12 million to 8.4 million shares. And Redmile Group LLC has lifted its position by 3.85% or 0.23 million shares – to 6.28 million shares.
With over 5.95 million Atara Biotherapeutics Inc (ATRA) shares trading Monday and a closing price of $0.56 on the day, the dollar volume was approximately $3.33 million. The shares have shown a negative half year performance of -71.54% and its price on 01/08/24 gained nearly 25.28%. Currently, there are 95.93M common shares owned by the public and among those 95.93M shares have been available to trade.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
An analysis of what Wall Street brokers have to say about the expected price targets for this stock gives us this picture: 7 analysts who have offered their price forecasts for ATRA have a consensus price objective of $4.83. The analysts have set the share’s price value over the next 12 months at a high of $13.00 and a low of $0.50. The average price target is 88.41% above its recent price level and a downside to the estimated low will see the stock lose -12.0% over that period. But an upside of 95.69% will see the stock hit the forecast high price target while median target price for the stock is $2.90.
Insiders at the company have transacted a total of 39 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 15 of these insider trades were purchases, accounting for 1,976,939 shares. Insider sales of the common stock occurred on 24 occasions, with total insider shares sold totaling 186,805 shares.
The top 3 mutual fund holders in Atara Biotherapeutics Inc are Wasatch Ultra Growth Fund, Vanguard Total Stock Market ETF, and iShares Russell 2000 ETF. Wasatch Ultra Growth Fund owns 3.22 million shares of the company’s stock, all valued at over $2.13 million. The company bought an additional 1.34 million shares recently to bring their total holdings to about 3.16% of the shares outstanding. iShares Russell 2000 ETF bought 1158.0 shares to bring its total holdings to over 2.36 million shares at a value of $1.56 million. iShares Russell 2000 ETF now owns shares totaling to 2.31% of the shares outstanding.
However, the script later moved the day high at 0.5717, up 25.28%. The company’s stock has a 5-day price change of 8.23% and -60.64% over the past three months. ATRA shares are trading 8.23% year to date (YTD), with the 12-month market performance down to -84.41% lower. It has a 12-month low price of $0.20 and touched a high of $5.64 over the same period. ATRA has an average intraday trading volume of 4.82 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -1.85%, -21.53%, and -66.97% respectively.
Institutional ownership of Atara Biotherapeutics Inc (NASDAQ: ATRA) shares accounts for 98.12% of the company’s 95.93M shares outstanding. Mutual fund holders own 29.92%, while other institutional holders and individual stakeholders account for 68.09% and 13.20% respectively.
It has a market capitalization of $56.57M and a beta (3y monthly) value of 0.65. The earnings-per-share (ttm) stands at -$2.77. Price movements for the stock have been influenced by the stock’s volatility, which stands at 15.29% over the week and 14.29% over the month.
Analysts forecast that Atara Biotherapeutics Inc (ATRA) will achieve an EPS of -$0.54 for the current quarter, -$0.4 for the next quarter and -$1.42 for 2024. The lowest estimate earnings-per-share for the quarter is -$0.62 while analysts give the company a high EPS estimate of -$0.38. Comparatively, EPS for the current quarter was -$0.72 a year ago. Earnings per share for the fiscal year are expected to decrease by -11.24%, and 53.31% over the next financial year.
Looking at the support for the ATRA, a number of firms have released research notes about the stock. Mizuho stated their Neutral rating for the stock in a research note on November 09, 2023, with the firm’s price target at $31-$1.
